Search Results - "KIRSTEIN, Mark N"

CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation by Takahashi, Takuto, Mohamud, Maryam A, Smith, Angela R, Jacobson, Pamala A, Jaber, Mutaz M, Alharbi, Abeer F, Fisher, James, Kirstein, Mark N

“…Prophylactic voriconazole use is recommended for children undergoing hematopoietic cell transplantation (HCT). Dosing considerations are essential, due to the…”
Get full text

Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1 by Osum, Sara H., Oribamise, Eunice I., Corbière, Stanislas M.A.S., Taisto, Mandy, Jubenville, Tyler, Coutts, Alex, Kirstein, Mark N., Fisher, James, Moertel, Christopher, Du, Ming, Bedwell, David, Largaespada, David A., Watson, Adrienne L.

“…Neurofibromatosis type 1 (NF1) results from germline mutations in the tumor-suppressor gene NF1 and predisposes patients to developing nervous system tumors…”
Get full text

Cytotoxic Effect of Zoledronic Acid-Loaded Bone Cement on Giant Cell Tumor, Multiple Myeloma, and Renal Cell Carcinoma Cell Lines by Zwolak, Pawel, Manivel, J Carlos, Jasinski, Piotr, Kirstein, Mark N, Dudek, Arkadiusz Z, Fisher, James, Cheng, Edward Y

“…BACKGROUND:Local recurrence with subsequent osteolysis is a problem after intralesional curettage of giant cell tumor of bone, myeloma, and metastatic…”
Get full text

High-performance liquid chromatographic method for the determination of gemcitabine and 2′,2′-difluorodeoxyuridine in plasma and tissue culture media by Kirstein, Mark N., Hassan, Iman, Guire, Dan E., Weller, Dennis R., Dagit, Jason W., Fisher, James E., Remmel, Rory P.

“…Gemcitabine, a pyrimidine antimetabolite undergoes metabolism by plasma and liver cytidine deaminase to form the inactive compound, 2′,2′-difluorodeoxyuridine…”
Get full text

Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid by Khatri, Amit, Gaber, M. Waleed, Brundage, Richard C., Naimark, Michael D., Hanna, Suzan K., Stewart, Clinton F., Kirstein, Mark N.

“…Purpose Anticancer agents are useful for treating brain tumors, but sub therapeutic concentrations due to decreased blood–brain barrier (BBB) penetration limit…”
Get full text

Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin's Lymphoma by Morris, Stephan W., Kirstein, Mark N., Valentine, Marcus B., Dittmer, Kristopher G., Shapiro, David N., Saltman, David L., Look, A. Thomas

“…The 2;5 chromosomal translocation occurs in most anaplastic large-cell non-Hodgkin's lymphomas arising from activated T lymphocytes. This rearrangement was…”
Get full text

Predictive Value of C‐Reactive Protein and Albumin for Temporal Within‐Individual Pharmacokinetic Variability of Voriconazole in Pediatric Patients Undergoing Hematopoietic Cell Transplantation by Takahashi, Takuto, Jaber, Mutaz M., Smith, Angela R., Jacobson, Pamala A., Fisher, James, Kirstein, Mark N.

“…Voriconazole is a widely used antifungal agent in immunocompromised patients, but its utility is limited by its variable exposure and narrow therapeutic index…”
Get full text

Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients by Takahashi, Takuto, Smith, Angela R, Jacobson, Pamala A, Fisher, James, Rubin, Nathan T, Kirstein, Mark N

“…Voriconazole (VCZ) is an antifungal agent with wide inter- and intrapatient pharmacokinetic (PK) variability and narrow therapeutic index. Although obesity was…”
Get full text

Influence of Renal Function on Phosphoramide Mustard Exposure: A Nonlinear Mixed‐Effects Analysis by Jaber, Mutaz M., Takahashi, Takuto, Kirstein, Mark N., Al‐Kofahi, Mahmoud, Jacobson, Pamala A., Brundage, Richard C.

“…Phosphoramide mustard (PM) is the final cytotoxic metabolite formed from the parent compound cyclophosphamide through a complex metabolic pathway, primarily…”
Get full text

A Pilot Study of Protracted Topotecan Dosing Using a Pharmacokinetically Guided Dosing Approach in Children with Solid Tumors by SANTANA, Victor M, ZAMBONI, William C, KIRSTEIN, Mark N, MING TAN, TIEBIN LIU, GAJJAR, Amar, HOUGHTON, Peter J, STEWART, Clinton F

“…Purpose: To assess the use of a pharmacokinetically guided topotecan strategy and evaluate the toxicity of protracted i.v. topotecan in children with recurrent…”
Get full text

CYP51A1 polymorphism and voriconazole-associated hepatotoxicity in children undergoing hematopoietic cell transplant by Takahashi, Takuto, Smith, Angela R, Jacobson, Pamala A, Alharbi, Abeer F, Fisher, James, Rubin, Nathan T, Kirstein, Mark N

“…Fungal (14α-sterol demethylase) is the target of an azole antifungal, voriconazole (VCZ), which also partially inhibits human . Hepatotoxicity is a common…”
Get full text

A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation by Knight-Perry, Jessica, Jennissen, Cathryn, Long, Susie E., Hage, Stefanie, DeFor, Todd E., Chan, Wing T., Fisher, James, Kirstein, Mark N., Smith, Angela R.

“…To optimize voriconazole dosing in pediatric hematopoietic cell transplantation (HCT), we conducted a phase I study with a modified 3 + 3 dose-escalation…”
Get full text

Pharmacokinetic–pharmacodynamic modelling of acute N‐terminal pro B‐type natriuretic peptide after doxorubicin infusion in breast cancer by Liang, Shuang, Brundage, Richard C., Jacobson, Pamala A., Blaes, Anne, Kirstein, Mark N.

“…Aims The aim of the present study was to develop a pharmacokinetic–pharmacodynamic (PK‐PD) model to characterize the relationship between plasma doxorubicin…”
Get full text

Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion by Alharbi, Abeer F., Kratzke, Robert A., D’Cunha, Jonathan, Maddaus, Michael Anthony, Sanghavi, Kinjal, Kirstein, Mark N.

“…Purpose We investigated the safety, pharmacokinetics, and efficacy of gemcitabine administered via bronchial artery infusion (BAI) and IV infusion in advanced…”
Get full text

Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning by Sanghavi, Kinjal, Wiseman, Anthony, Kirstein, Mark N, Cao, Qing, Brundage, Richard, Jensen, Kyle, Rogosheske, John, Kurtzweil, Andy, Long-Boyle, Janel, Wagner, John, Warlick, Erica D, Brunstein, Claudio G, Weisdorf, Daniel J, Jacobson, Pamala A

“…Patients undergoing hematopoietic cell transplantation (HCT) with reduced intensity conditioning (RIC) commonly receive fludarabine. Higher exposure of…”
Get full text

Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis by Takahashi, Takuto, Jaber, Mutaz M., Al-Kofahi, Mahmoud, Weisdorf, Daniel, Brunstein, Claudio, Bachanova, Veronika, Brundage, Richard C., Jacobson, Pamala A., Kirstein, Mark N.

“…•Dose adjustment of cyclophosphamide (CY) for obesity is widely conducted•We simulated exposure of 8 dosing strategies for obesity in a single dose CY 50…”
Get full text

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 by Isakson, Sara H., Rizzardi, Anthony E., Coutts, Alexander W., Carlson, Daniel F., Kirstein, Mark N., Fisher, James, Vitte, Jeremie, Williams, Kyle B., Pluhar, G. Elizabeth, Dahiya, Sonika, Widemann, Brigitte C., Dombi, Eva, Rizvi, Tilat, Ratner, Nancy, Messiaen, Ludwine, Stemmer-Rachamimov, Anat O., Fahrenkrug, Scott C., Gutmann, David H., Giovannini, Marco, Moertel, Christopher L., Largaespada, David A., Watson, Adrienne L.

“…Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 ( NF1 ). NF1 patients present with a variety of clinical…”
Get full text

Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens by KIRSTEIN, Mark N, BRUNDAGE, Richard C, ELMQUIST, William F, REMMEL, Rory P, MARKER, Paul H, GUIRE, Dan E, YEE, Douglas

“…A dynamic 3-dimensional tissue culture system has been developed that will allow for control of gemcitabine exposure to mimic concentration-time profiles…”
Get full text

Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection by Bai, Feng, Kirstein, Mark N, Hanna, Suzan K, Iacono, Lisa C, Johnston, Brad, Stewart, Clinton F

“…Topotecan (TPT) undergoes hepatic N-demethylation forming N-desmethyl topotecan (NDS). To evaluate the effect of drug–drug interactions on NDS disposition in…”
Get full text

Erratum: Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS) by Shapiro, Alice C., Adlis, Susan A., Robien, Kim, Kirstein, Mark N., Liang, Shuang, Richter, Sara A., Lerner, Rachel E.

Get full text